BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Dutch biotech firm Synaffix announces first partnership with Korean company

February 8, 2023 | News

Chong Kun Dang Pharm licenses Synaffix ADC technology



Synaffix B.V., a Dutch biotechnology company focused on commercialising its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Chong Kun Dang Pharm (CKD), a global pharmaceutical company based in South Korea, have entered a licensing agreement.

The agreement provides CKD a license for global, target-specific rights to Synaffix's proprietary ADC technology, adding a new ADC drug candidate to CKD's pipeline. CKD will have access to Synaffix's ADC technologies, comprising *GlycoConnect, HydraSpace* and an undisclosed linker-payload from the *toxSYN* platform.

Under the terms of the agreement, Synaffix has received an upfront payment and is eligible to receive further milestone payments plus royalties on commercial sales. CKD will be responsible for the research, development, manufacturing and commercialisation of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.

Young-Joo, Kim, Chief Executive Officer of CKD Pharm said: "By combining our existing oncology expertise and related technologies with the ADC platform of Synaffix, we have been able to efficiently establish a novel ADC candidate for CKD's pipeline. CKD's work is deeply rooted in oncology, and we are committed to improving the quality of life for patients by developing highly targeted novel drugs for the treatment of cancer."